Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease

Neurodegenerative Diseases

Volumn 4, Issue 6, 2007, Pages 403-405

  Irizarry, M C ^a,c   Yao, Y ^b   Hyman, B T ^a   Growdon, J H ^a   Pratico D ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Isoprostanes; Mild cognitive impairment; Oxidative stress; Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; ISOPROSTANE; PROSTAGLANDIN F2 ALPHA;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; DISEASE MARKER; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MEMORY DISORDER; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; F2-ISOPROSTANES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; PARKINSON DISEASE;

EID: 35048845219     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000107699     Document Type: Article

References (17)

1. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-1783.
2. Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ: Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001;158:293-297.
3. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD: Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562-565.
4. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA: Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-812.
5. 2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 2001;125:510-512.
6. Grossman M, Farmer J, Leight S, Work M, Moore P, Van D, V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM: Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721-729.
7. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972-976.
8. 2-isoprostane levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimers Rep 1999;2:277-282.
9. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, Rayssiguier Y, Jalenques I, Mazur A: Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med 1999;27:463-469.
10. 4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002;52:175-179.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
13. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
14. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC: Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60:958-964.
15. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147:1-10.
16. Blessed G, Tomlinson BE, Roth M: Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull 1988;24:705-708.
17. Basu S, Helmersson J: Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 2005;7:221-235.